Published in final edited form as:

Med Decis Making. 2013 May ; 33(4): 521–532. doi:10.1177/0272989X12470755.

Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer

Mehmet U.S. Ayyaci, PhD¹, Jinghua Shi, PhD², Oguzhan Alagoz, PhD³, and Sam Lubner, MD⁴

¹Information Systems and Operations Management, University of Texas at Dallas

²China Minsheng Banking Corporation, Beijing, P.R. China

³Department of Industrial and Systems Engineering, University of Wisconsin-Madison

⁴Carbone Comprehensive Cancer Center, University of Wisconsin-Madison

Abstract

Purpose—We evaluated the cost-effectiveness of adjuvant chemotherapy using 5-fluorouracil, leucovorin (5FU/LV), and oxaliplatin (FOLFOX) compared with 5FU/LV alone and 5FU/LV compared with observation alone for patients who had resected stage II colon cancer.

Methods—We developed two Markov models to represent the adjuvant chemotherapy and follow-up periods and a single Markov model to represent the observation group. We used calibration to estimate the transition probabilities among different toxicity levels. The base-case considered 60-year-old patients who had undergone an uncomplicated hemicolectomy for stage II colon cancer and was medically fit to receive 6 months of adjuvant chemotherapy. We measured health outcomes in quality-adjusted life-years (QALYs) and estimated costs using 2007 US\$.

Results—In the base-case, adjuvant chemotherapy of FOLFOX regimen had an incremental cost-effectiveness ratio (ICER) of \$54,359/QALY compared with the 5FU/LV regimen and the 5FU/LV regimen had an ICER of \$14,584/QALY compared with the observation group from the third-party payer perspective. The ICER values were most sensitive to 5-year relapse probability, cost of adjuvant chemotherapy, and the discount rate for the FOLFOX arm, whereas the ICER value of 5FU/LV was most sensitive to the 5-year relapse probability, 5-year survival probability, and the relapse cost. The probabilistic sensitivity analysis indicate that the ICER of 5FU/LV is less than \$50,000/QALY with a probability of 99.62% and the ICER of FOLFOX as compared to 5FU/LV is less than \$50,000/QALY and \$100,000/QALY with a probability of 44.48% and 97.24%, respectively.

Conclusion—While adjuvant chemotherapy with 5FU/LV is cost-effective at all ages for patients who had undergone an uncomplicated hemicolectomy for stage II colon cancer, FOLFOX is not likely to be cost-effective as compared to 5FU/LV.

Keywords

Colon Cancer; Stage II; Cost-effectiveness; Markov Model; Calibration

Introduction

In 2012, 143,000 new cases of colorectal cancer are estimated¹. Behind lung cancer, colorectal cancer is the second-leading cause of cancer death^{2–3}. Survival rates over the last two decades have improved, primarily due to advances in screening, diagnosis, and treatment. For example, the introduction of 5-FU based adjuvant chemotherapy in the late 1980s reaped a 30% mortality reduction for stage III colon cancer². Since 1990, 5-FU based adjuvant chemotherapy has been acknowledged as the standard of care for stage III colon cancer. The FOLFOX regimen (oxaliplatin, 5-FU, and leucovorin) has been established as a widely accepted standard for adjuvant therapy in stage III colon cancer based on the MOSAIC trial since its publication in 2004⁴. The cost-effectiveness of adjuvant FOLFOX compared to 5FU/LV (5-FU and leucovorin) in the stage III setting has been analyzed and described by Eggington and colleagues, with an acceptable cost/QALY of £2970 (\$3800) for the addition of oxaliplatin⁵.

The benefit of 5FU/LV based adjuvant chemotherapy for unselected stage II colon cancer patients is uncertain. In order to address this uncertainty, several studies focused on estimating the magnitude of the benefit. An earlier study included 1,016 stage II patients and found that the 5-year survival was 80% for untreated patients and 82% for patients treated with FU+leucovorin, where the survival difference was not statistically significant⁶. The QUASAR study conducted a large-scale randomized trial on 3239 patients (91% with stage II disease) in order to explore the effectiveness of adjuvant chemotherapy for stage II colorectal cancer⁷. This study found that 5-year survival without and with adjuvant chemotherapy are 80% and 83.6%, respectively. A recent study demonstrated the potential utility of adjuvant chemotherapy in stage II colon cancer based on the data of 20,898 patients from 18 randomized trials. This study reported that 8-year survival of patients undergoing adjuvant chemotherapy improved from 66.8% to 72.2% ($P=0.026$) when compared to the observation alone⁸.

There is also uncertainty around the risk/benefit of addition of oxaliplatin to 5-FU for adjuvant treatment of stage II colon cancer which has been considered in the MOSAIC study⁹. The MOSAIC study suggests an improvement from 84.3% to 87% of 3-year disease-free-survival in stage II colon cancer patients with the addition of oxaliplatin to 5FU/LV treatment: a small, albeit consistent survival benefit. However, the benefit up to this point has been too small to merit the widespread use of adjuvant chemotherapy for stage II colon cancer.

Overall, while these studies found a small benefit in overall survival with adjuvant chemotherapy for both 5FU/LV and FOLFOX in stage II colon cancer¹⁰, it is still not clear whether this small gain outweighs additional burden of this treatment due to cost and toxicity¹¹. In the most recently updated data of the MOSAIC trial, the benefit of FOLFOX over 5FU/LV was small in stage II disease; and no comparison was made to observation alone¹². Therefore, adjuvant chemotherapy using 5FU/LV may have a better ICER for stage II colon cancer since it has similar efficacy and is less costly than oxaliplatin-containing regimens. The purpose of this study is to investigate whether or not the use of FOLFOX as compared to 5FU/LV and 5FU/LV as compared to observation is cost-effective for patients who have had primary surgery for stage II colon cancer.

Methods

We constructed two Markov models to estimate the incremental cost-effectiveness of treating post-surgery patients who had stage II colon cancer with adjuvant chemotherapy using FOLFOX compared with 5FU/LV and those using 5FU/LV compared with no

treatment. We performed an analysis from the third-party payer perspective which includes only the direct medical costs. We used quality-adjusted life-years (QALYs) to evaluate the effectiveness of the treatments. We considered 60-year-old patients with stage II colon cancer as our base case because of the median ages of the two important data sources in our research: QUASAR⁷ and MOSAIC¹². They had undergone a hemicolectomy for stage II colon cancer, recovered, and were medically fit to receive 6 months of adjuvant FOLFOX or 5FU/LV chemotherapy. We discounted costs and benefits by 3% per year.

Markov Models

We built two Markov models that represent the adjuvant chemotherapy period and follow-up period for patients who had stage II colon cancer and the same Markov model applies to both regimens with different parameters. We individually simulate 5000 patients using the Markov models and implement the simulation in JAVA programming environment.

1) Adjuvant chemotherapy period model—Our Markov model for the adjuvant chemotherapy period consists of the following five states (Figure 1A): well (state 1), minor toxicity (state 2), major toxicity (state 3), quitting adjuvant chemotherapy (state 4), and death due to adjuvant chemotherapy (state 5). We assumed that the transitions among those five states were Markovian. Following the Common Toxicity Criteria of the National Cancer Institute¹³, version 3, we used three levels (well, minor toxicity and major toxicity) to represent the toxicity of adjuvant chemotherapy where “well” represents no toxicity (Grade 0); “minor toxicity” represents mild or moderate adverse effects (Grade 1 and 2); “major toxicity” represents severe or life-threatening adverse effects (Grade 3 and 4)¹⁴. We set the cycle length of the Markov model as one month, that is, the transitions occur on a monthly basis. The Markov model runs for 6 months. In order to have truly stage II disease, it would have to be established with surgery and pathologic analysis of the colon and lymph nodes. The surgery that is performed is a hemicolectomy. We initialize all patients to begin in state 1 (free of cancer) at the start of the adjuvant chemotherapy since we model the patients who had undergone an uncomplicated hemicolectomy for stage II colon cancer.

2) Follow-up period model—Patients without adjuvant chemotherapy (observation group) move directly to the follow-up period after the resection. Patients who receive adjuvant chemotherapy (chemotherapy groups) enter the follow-up period after the adjuvant chemotherapy that lasts for 6 months. We modeled the follow-up period using the following three states (Figure 1B): free of cancer (state 1), alive with relapse (state 2), and death (state 3). The total follow-up time is five years. We set the cycle length as one year for the observation group. On the other hand, since the chemotherapy group undergoes treatment for 6 months, we set the follow-up period as 4.5 years, where the cycle length is 6 months for the first cycle and 1 year for the subsequent cycles. We apply annual transition probabilities for the initial 6-months cycle. Therefore, the overall duration for the chemotherapy group is also 5 years.

Assumptions

Patients endure different grades of toxicity during chemotherapy due to the toxicity accumulation and toxicity alleviation measures such as dose reduction, delay and growth factor use, if necessary. In order to accurately evaluate the QALYs of the patients during the chemotherapy period, it is necessary to model toxicity dynamically instead of setting it constant during the six months. However, the lack of the intermediate toxicity data hinders such attempt. To overcome this problem, we used *calibration*, a commonly used method in cancer simulation models^{15–17}, to estimate the intermediate toxicity parameters using final toxicity values (i.e., overall percentages of well (P_w)/minor toxicity (P_{mi})/major toxicity (P_{ma})/quitting adjuvant chemotherapy (P_q)/death due to adjuvant chemotherapy (P_d))¹⁸,

which is described in more detail in the next subsection. During months 1 to 6, we modeled the toxicity progression using the Markov model representing the adjuvant chemotherapy period and assumed that no patients relapse. This is justified because relapse is unlikely at this point.

For the follow-up period model, we ignored the differences between the relapse probability of the patients in the chemotherapy groups and that of the patients in the observation group after five years due to limited data. More specifically, we assumed that the relapse rate after year five is zero and we calculated the life expectancy of the patients without relapse at the end of the follow-up period using United States Life Tables¹⁹. However, the patients who are relapsed and are alive at the beginning of the 6th year continue to be simulated in the follow-up model using respective mortality probabilities until they reach the death state. Note that each patient has been simulated individually in the Markov simulation model.

Calibration process

We denoted the transition probabilities of the adjuvant chemotherapy model by P_{w-w} , P_{w-mi} , P_{w-ma} , P_{mi-w} , P_{mi-mi} , P_{mi-ma} , P_{ma-w} , P_{ma-mi} , P_{ma-ma} , P_{ma-q} , and P_{ma-d} , where subscript “w” represents well state; “mi” represents minor toxicity state; “ma” represents major toxicity state; “q” represents quitting adjuvant chemotherapy state; and “d” represents death due to adjuvant chemotherapy state. For example, P_{w-mi} represents the probability that a patient who is in well state in the current month will move to minor toxicity state in the next month. Among these probabilities, we calculated P_{w-w} as 0.66 directly using the following equation: $P_w = (P_{w-w})^6$, where P_w is shown in Table 1. We derived some other probabilities (P_{w-mi} , P_{mi-ma} , and P_{ma-mi}) directly as well, e.g. $P_{w-mi} = 1 - P_{w-w} - P_{w-ma}$. In order to estimate the remaining parameters, we used a calibration method¹⁶, which proceeds as follows:

- Step 1:** We defined a plausible value range and a step size for each probability parameter based on expert opinion. For example, we set P_{w-ma} in [0.01, 0.1] and P_{ma-d} in [0, 0.04] with a step size of 0.01, P_{mi-w} in [0.30, 0.80], P_{mi-mi} in [0.20, 0.50], P_{ma-w} in [0, 0.30], P_{ma-ma} in [0, 0.30], and P_{ma-q} in [0, 0.20] with a step size of 0.02.
- Step 2:** Using each combination of these parameters, we simulated the toxicity transition trajectories for a cohort of 5000 patients. We classified each patient according to his/her most advanced toxicity level. For example, after 6 months, if the patient experienced well, minor and major toxicity, we classified her/him as a patient with major toxicity. Then, for each parameter combination, we calculated the corresponding values from the output statistics, i.e. overall percentages of well (P_w'), minor toxicity (P_{mi}'), major toxicity (P_{ma}'), and quitting adjuvant chemotherapy (P_q'), and death due to adjuvant chemotherapy (P_d') which are presented in Table 1.
- Step 3:** For each combination of these parameters, we compared the values of the corresponding output statistics (P_{ma}' , P_{mi}' , P_w' , P_d' and P_q') with the actual data (P_{ma} , P_{mi} , P_w , P_d and P_q (Table 1)) by calculating the total square error (TSE)¹⁴. We then selected the parameter combination with the minimum TSE.

$$TSE = (P_{ma} - P_{ma}')^2 + (P_{mi} - P_{mi}')^2 + (P_w - P_w')^2 + (P_d - P_d')^2 + (P_q - P_q')^2$$

Our calibration process has generated the following parameter values that are used in the adjuvant chemotherapy period model for FOLFOX regimen, $P_{w-ma}=0.03$, $P_{mi-w}=0.36$,

$P_{mi-mi}=0.32$, $P_{ma-w}=0.1$, $P_{ma-ma}=0.3$, $P_{ma-q}=0.2$, $P_{ma-d}=0.01$; and for 5FU/LV regimen, $P_{w-ma}=0.03$, $P_{mi-w}=0.36$, $P_{mi-mi}=0.32$, $P_{ma-w}=0.1$, $P_{ma-ma}=0.3$, $P_{ma-q}=0.2$, $P_{ma-d}=0.01$.

Base-Case Parameters

All parameters used in the base-case analysis including probabilities, utilities, and costs are listed in Table 1–5.

Several clinical studies report on the incidence of toxic effects due to 5FU/LV or FOLFOX^{4, 12, 20}. We use the toxicity values reported in the MOSAIC trial for both treatment arms where we define the highest incidence of toxicity events with grade 3 or higher grade as “major toxicity”, the remaining patients with the incidence of any toxicities as “minor toxicity”, and the patients with no gradable toxicity as “well”. Although the data used for estimation come from a mixed cohort of stage II and stage III patients which may amplify the toxicity values for stage II patients, overestimation of toxicity is preferable rather than underestimation in this analysis in favor of conservative and reliable conclusions.

In the follow-up period, as the cancer relapse probabilities were time dependent²¹, we used an annual transition probability from state 1 (free of cancer) to state 2 (alive with relapse) instead of the stationary transition probability for those 5 years. First, we estimated the 1-year to 5-year relapse probabilities of the observation group and chemotherapy groups with FOLFOX and 5FU/LV using the Kaplan-Meier relapse curve of QUASAR trial⁷ and the Kaplan-Meier disease-free survival (DFS) curve of MOSAIC trial¹², respectively. We assumed that “1-DFS” was equal to the relapse probability, which was a conservative estimation for the impact of FOLFOX because it was slightly higher than the actual relapse probability. We obtained the 5-year survival probability of the observation group from the QUASAR trial⁷ and the 5-year survival probability of the chemotherapy groups from the 6-year survival probability of MOSAIC trial¹². Second, using those data, we derived the annual transition probabilities from state 1 to state 2 accordingly²².

For example, the 1-year and 2-year relapse probabilities are 2% and 9% for the FOLFOX chemotherapy group. Then, the transition probability from state 1 to 2 in year 1 under FOLFOX therapy (P_1^{1-2}) is easily computed as 0.02. The transition probability from state 1 to 2 in year 2 under FOLFOX therapy is calculated as follows: $(1-0.02)*P_2^{1-2}+0.02=0.09$, then $P_2^{1-2}=0.0714$. Similar calculations hold for the 5FU/LV therapy using respective parameters. The transition probabilities from state 1 (free of cancer) to state 3 (death) are obtained using United States Life Tables¹⁹. The calculation of the transition probabilities from state 2 (alive with relapse) to state 3 (death) proceeds as follows. Let x , y , and z represent the transition probabilities from state 2 (alive with relapse) to state 3 (death) for the FOLFOX, 5FU/LV and observation groups, respectively. We assume that x , y , and z are constant from years 1 to 5. Table 3 presents the computations to find x , y , and z . In Table 2, the 5-year death probability is taken as 13% for the chemotherapy groups since the 5-year survival probability is 87% as shown in Table 2. Similarly, the 5-year death probability for the observation group is 20%. Table 3 uses the fact that summation of deaths through years 1 to 5 is equal to the 5-year death probability to calculate x , y , and z .

We expressed all costs in 2007 U.S. dollars. Two separate studies reported the cost of FOLFOX and 5FU/LV as \$29,000 and \$6,500 in the year of 2007²³, and \$34,628 and \$765 in the year of 2004²⁴, respectively. We chose the most recent cost report for our base-case analysis. Despite the fact that these cost figures are from 2007, Medicare billing rates have been flat for these regimens for the last five years therefore are applicable for the cost-effectiveness calculations. Note that we included the most costly adverse effects in our analysis and used the corresponding incidence rates for cost calculations.

We use several studies to estimate the utility of adjuvant chemotherapy for patients. An important component for utilities is the utility of patients without adjuvant chemotherapy. Considering the surgery before chemotherapy, we applied a slightly lower utility than a healthy individual²⁵ to the “well” state based on a study by Ramsey and his colleagues who showed that patients without adjuvant chemotherapy had a utility of 0.84²⁶. We used the same study to estimate the utilities from year 2 through year 5. For minor toxicity, we calculated the utility by computing the mean of the utilities of the patients suffering from mild (0.785) and moderate neuropathy (0.679) in the patients receiving adjuvant chemotherapy. For major toxicity, we used the average utility of patients with severe neuropathy (0.585). On the other hand, we set the utility of patients who are well between the 6th and 12th month of the chemotherapy group and the first year of the observation group to 0.84, which is the utility for the patients who are well during chemotherapy.

Sensitivity Analysis

We also conducted an extensive sensitivity analysis, in which we tested the effect of uncertainty in clinically important parameters. We found the ranges for the sensitivity analysis using available published data, and otherwise we varied them within 20% of the mean estimates as shown in Tables 2, 4, and 5. When the 5-year relapse probability varied, we adjusted the 1-year to 5-year relapse probability using the same distribution as shown in the base case. Afterwards, we updated the transition probabilities from state 1 (free from cancer) to 2 (alive with relapse) and state 2 (alive with relapse) to 3 (death) accordingly.

We ran our model for patients in different ages between 50 and 80 years old. We calculated age-based ICER values assuming all parameters except the mortality rates are kept constant. In addition to the above analysis, we re-calculated the ICER when non-medical costs such as costs due to the workdays lost caused by adjuvant chemotherapy are included in the analysis. This is especially important for the patients that are younger than or equal to 65. Furthermore, we conducted a probabilistic sensitivity analysis to address the uncertainty around some of the parameters. Because the available data for the uncertain parameters was in the form a range with a midpoint or a most likely value obtained from a large clinical study, we assumed a triangular distribution around the uncertain parameter values. We defined the base case value as the mode, minimum value reported in the literature (or the lower bound) as the lower limit, and the maximum value reported in the literature (or the upper bound) as the upper limit of the triangular distribution as shown in Tables 2, 4, and 5. We obtained probabilities of cost-effectiveness by using common random numbers when comparing the alternatives. Although there is no absolute cost-effectiveness threshold value, we used \$50,000/QALY as a reference value in this research. Note that the costs as mentioned in this study correspond to the prices and therefore the third party payer's perspective is taken.

Results

In the base case analysis, the patient receiving adjuvant chemotherapy with 5FU/LV regimen gained 0.38 QALYs at a cost of \$5,245 as compared to the observation and the patient receiving adjuvant chemotherapy with FOLFOX regimen gained 0.37 QALYs at a cost of \$20,113 as compared to the 5FU/LV regimen (Table 3). Consequently, the incremental cost-effectiveness ratio (ICER) of adjuvant chemotherapy with FOLFOX was 54,359/QALY and adjuvant chemotherapy with 5FU/LV was 14,584/QALY. In an analysis of life-years (LYs) saved, without quality weights, the adjuvant chemotherapy with FOLFOX yielded 14.28 LYs, 5FU/LV yielded 13.90 LYs and the observation group yielded 13.34 LYs. Therefore, the ICER of adjuvant chemotherapy with FOLFOX and 5FU/LV was \$52,929/LY and \$9,896/LY, respectively.

Figure 2A and 2B presents the tornado diagrams that summarize the results of the one-way sensitivity analysis for parameters that significantly change the ICER values, where the vertical solid line represents the ICER values under base case. The ICER values of FOLFOX are most sensitive to the 5-year relapse probability, cost of adjuvant chemotherapy, and the discount rate whereas the ICER values of 5FU/LV are most sensitive to the 5-year relapse probability, 5-year survival probability, and the relapse cost. The results are least sensitive (not shown in the tornado diagram) to the percentage of chemotherapy-induced toxicity and its cost (Grade 3–4 neutropenia, Grade 3–4 febrile neutropenia (Hospitalization), and Grade 3–4 diarrhea).

Figure 3 displays the results of sensitivity analysis for various ages, which shows that ICER of the adjuvant chemotherapy with FOLFOX as compared to 5FU/LV is increasing exponentially with age, especially when the patient is older than 65 years old. The ICER of the adjuvant chemotherapy with 5FU/LV as compared to observation also increases by age, but rather at a much smaller rate when compared to the ICER of FOLFOX.

Next, we conducted a sensitivity analysis on cost perspective such that the costs due to the workdays lost caused by adjuvant chemotherapy are considered. Restricted by the limited data on the financial impact of toxicity of adjuvant chemotherapy, we made a compromising assumption that all unretired patients younger than or equal to 65 did not work during the full six months of adjuvant chemotherapy at all. As the annual average wage in 2003 of US was \$40,405²⁷ and approximately 52.8%²⁸ patients were labor force participations when they were 60 years old, the ICER increased to \$42,655/QALY for 5FU/LV. For patients who were 50 years old, 80.4%²⁸ of them were not retired so that the ICER increased from \$11,560/QALY to \$45,399/QALY for 5FU/LV. The unretired percentage of patients shrank sharply to 16%²⁸ for 65-year-old people or older, so that ICER of 65-year-old patients increased from \$17,234/QALY to \$27,336/QALY for 5FU/LV.

We also performed a probabilistic sensitivity analysis for the uncertain parameters (Figure 4). The probability of the cost-effectiveness of LV5VU2 as compared to the observation was 99.62% with a \$50,000/QALY threshold and 99.98% with a \$100,000/QALY threshold. On the other hand, the probability of the cost-effectiveness of FOLFOX as compared to the 5FU/LV was 44.48% with a \$50,000/QALY threshold and 97.24% with a \$100,000/QALY threshold. The mean of the ICERs were \$55,697/QALY and \$16,136/QALY for the FOLFOX and 5FU/LV, respectively.

Discussion

Compared to no postoperative treatment, adjuvant chemotherapy with 5FU/LV for stage II colon cancer achieves an ICER of \$14,584/QALY which is cost-effective with respect to the benchmark of \$50,000/QALY. However, adjuvant chemotherapy with FOLFOX for stage II colon cancer as compared to 5FU/LV is less likely to be cost-effective with a base case ICER of \$54,359/QALY. It is also reasonable to conclude that no matter whether the costs due to lost workdays are considered or not, 5FU/LV is cost-effective for people at all ages, whereas FOLFOX is cost-effective for patients younger than or equal to 55 only when the costs due to lost workdays are not considered. The cost-effectiveness ratio is most sensitive to 5-year relapse probability. Because of the uncertainty around some of the parameters used in our models, we conducted a probabilistic sensitivity analysis of these parameters. We found that the ICER of 5FU/LV is less than \$50,000/QALY almost surely and the ICER of FOLFOX as compared to 5FU/LV is less than \$50,000/QALY with 44.48% probability and it is less than \$100,000/QALY with 97.24% probability.

Because the data on the clinical utility of adjuvant chemotherapy for stage II colon cancer continues to evolve²⁹, a comparative cost-effectiveness analysis of various adjuvant chemotherapy regimens may appear to be premature. In fact, most studies focus on trials comparing the effects of adjuvant chemotherapy with observation instead of conducting a cost-effectiveness analysis. Our analysis is important to resolve the question of whether the probably a significant benefit due to chemotherapy in stage II patients¹¹ is justified in terms of cost and toxicity. Previous studies noted that there was probably a small benefit for adjuvant treatment of stage II colon cancer, so the most important question is whether this small benefit might prove to be clinically significant for recommendation as standard therapy. As a decision support tool, cost-effectiveness provides a useful methodology to pursue the answer.

It is well-known that not all stage II patients are likely to benefit equally from the adjuvant chemotherapy¹⁰. Patients with inadequate nodal sampling, nearly or completely obstructing tumors, lymphovascular invasion, or elevated CEA are thought to be at higher risk of relapse. O'Connell et al. stated³⁰ that according to the AJCC staging guidelines (6th edition), the 5-year stage-specific survival are: I (93.2%), IIa (84.7%), IIb (72.2%), IIIa (83.4%), IIIb (64.1%), IIIc (44.3%), and IV (8.1%). They argued that the 5-year survival of IIIa patients is significantly higher than that of stage IIb patients which may be explained by current clinical practice that stage III patients normally receive adjuvant chemotherapy, but stage II patients generally do not. No matter whether this conjecture is valid or not, those data suggests that it is preferable to study IIa and IIb separately. However, restricted by the limited data for differentiating outcomes between stage IIa and IIb and the effect of chemotherapy from the literature, we did not stratify stage II colon cancer further.

Going forward, advances in understanding of risk stratification for stage II colon cancer may aid the selection of who should receive adjuvant chemotherapy. Genes predictive of varying risk of recurrence, as well as sensitivity to 5-FU based chemotherapy (microsatellite instability, chromosome 18q loss of heterozygosity) have been identified and are in the process of being more fully validated. The difference in relapse-free survival between high and low risk groups within stage II was about 15–18%. Assessing risk at diagnosis would aid in the decision to undertake chemotherapy, and what kind, more straightforward. Data presented at the 2009 and 2010 American Society of Clinical Oncology Annual Meeting gave a window into risk stratification beyond T stage and nodal sampling using modern DNA sequencing technologies exploring genes that reflect tumor invasiveness and chemosensitivity^{31–33}. Using these tools may help risk stratify and gauge clinical efficacy further, allowing for a more complete discussion of risk/benefit of chemotherapy.

Similarly, as more patients reach retirement age, it is worth noting that the ICER of FOLFOX increases dramatically with age, as other medical comorbidity and death from non-cancer causes factors into the model. This cost-effectiveness analysis may help decision making to restrict multi-agent chemotherapy to those patients who are most fit to receive chemotherapy, and most likely to have expectations of non-cancer survival that extend beyond 10 years.

As we await the results of intergroup trials (ECOG 5202) looking to answer the question of feasibility/applicability of molecular markers in risk stratification, the cost-effectiveness of adjuvant chemotherapy can only be improved. Other trials underway look to lessen the amount of chemotherapy delivered from 6 months to three, and perhaps decrease some of the cumulative toxicity of oxaliplatin and decrease the cost of drug by half.

Other regimens including capecitabine, an oral formulation of 5-FU have been developed over the last decade. Capecitabine has the advantage of easier delivery and less cost for

administration, but increased cost of the drug. As we do not have the same kind of direct comparison of efficacy between capecitabine and FOLFOX in stage II disease, we did not include it specifically in this analysis. There is a body of literature to suggest that the efficacy is at least noninferior in stage III colon cancer³⁴, and the cost differential is minimal when including clinic time and administration costs³⁵.

Our conclusions are that it is likely to be cost effective to consider 5-FU+leucovorin based chemotherapy for stage II colon cancer. The addition of a more toxic and costly, but slightly more efficacious chemotherapy is less likely to be cost effective. Examining comparative cost-effectiveness in an area where there is continued clinical exploration and debate hopes to make the discussion more focused on the clinical efficacy than the concern for economic impact. Future trials dedicated to stratifying risk and quantifying benefit will be beneficial in future decision making regarding adjuvant chemotherapy.

Acknowledgments

This research is supported through grant 1UL1RR025011 from the CTSA program of NCRR NIH and grant CMII-0844423 from the National Science Foundation. The authors gratefully acknowledge financial support from China Scholarship Council as well.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2012; 62(1):10–29. 10.3322/caac.20138. [PubMed: 22237781]
2. Colorectal cancer facts & figures American Cancer Society 2008–2010. [cited April 21, 2010]; Available from: http://www.cancer.org/downloads/STT/F861708_finalforweb.pdf
3. Tumej JW, Shenoy PJ, Moore SG, Kauh J, Flowers C. A Markov Model Assessing the Effectiveness and Cost-Effectiveness of FOLFOX Compared With FOLFIRI for the Initial Treatment of Metastatic Colorectal Cancer. American Journal of Clinical Oncology. 2009; 32(1): 49–55. [PubMed: 19194125]
4. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med. Jun 3; 2004 350(23):2343–51. 2004. [PubMed: 15175436]
5. Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer. 2006; 95(9):1195–201. [PubMed: 17031407]
6. IMPACT B2: International Multicentre Pooled Analysis of B2 Colon Cancer Trials Investigators. Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer. Journal of Clinical Oncology. 1999;1356–63. [PubMed: 10334519]
7. QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007; 370:2020–9. [PubMed: 18083404]
8. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. Feb 20; 2009 27(6):872–7. [PubMed: 19124803]
9. Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, Schrag D, et al. Patterns of Adjuvant Chemotherapy Use in a Population-Based Cohort of Patients With Resected Stage II or III Colon Cancer. Journal of Clinical Oncology. Aug 20; 2011 29(24):3255–62. 2011. [PubMed: 21768462]
10. André T, Sargent D, Tabernero J, O'Connell M, Buyse M, Sobrero A, et al. Current Issues in Adjuvant Treatment of Stage II Colon Cancer. Annals of surgical oncology. 2006; 13(6):887–98. [PubMed: 16614880]
11. Mano M, Duhoux F. Colon Cancer: Update on Adjuvant Therapy. Clinical Colorectal Cancer. 2008; 7(3):178–83. [PubMed: 18621635]
12. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon

- Cancer in the MOSAIC Trial. *Journal of Clinical Oncology*. Jul 1; 2009 27(19):3109–16. 2009. [PubMed: 19451431]
13. CTCAE 3.0. 2006. [cited June 28, 2010]; Available from: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae3.pdf
 14. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Seminars in Radiation Oncology*. 2003; 13(3):176–81. [PubMed: 12903007]
 15. Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS. Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines. *Pharmacoeconomics*. 2009; 27(7):533–45. 10.2165/11314830-000000000-00000. [PubMed: 19663525]
 16. Fatih, S.; Erenay, AO.; Benerjee, Ritesh; Cima, Robert R. Modeling the Natural History of Metachronous Colorectal Cancer under Colonoscopy Screenings. 2009.
 17. Roberts S, Wang L, Klein R, Ness R, Dittus R. Development of a simulation model of colorectal cancer. *ACM Trans Model Comput Simul*. 2007; 18(1):1–30.
 18. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, et al. Systematic Overview of Cost-Utility Assessments in Oncology. *J Clin Oncol*. Sep 18; 2000 18(18):3302–17. 2000. [PubMed: 10986064]
 19. Arias, E. United States Life Tables, 2004. 2007.
 20. Maindrault-Goebel F, Louvet C, Andr T, Carola E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). *European Journal of Cancer*. 1999; 35(9):1338–42. [PubMed: 10658524]
 21. Yun HR, al LJLe. Local recurrence after curative resection in patients with colon and rectal cancers. *International Journal of Colorectal Disease*. 2008; 23:1081–7. [PubMed: 18688621]
 22. Brigitta UM, Monz H-HK. Cost Effectiveness of Adding Folinic Acid to Fluorouracil Plus Levamisole as Adjuvant Chemotherapy in Patients with Colon Cancer in Germany. *Pharmacoeconomics*. 2003; 21(10):709–19. [PubMed: 12828493]
 23. Aballéa S, Chancellor JVM, Raikou M, Drummond MF, Weinstein MC, Jourdan S, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. *Cancer*. 2007; 109(6):1082–9. 10.1002/cncr.22512. [PubMed: 17265519]
 24. Schrag D. The Price Tag on Progress -- Chemotherapy for Colorectal Cancer. *N Engl J Med*. Jul 22; 2004 351(4):317–9. 2004. [PubMed: 15269308]
 25. Fryback DG, Lawrence Wf. Dollars May Not Buy as many QALYs as we think: a problem with defining QALY adjustments. *Med Decision Making*. 1997; 17:276–84.
 26. Ramsey SD, Andersen MR. Quality of life in survivors of colorectal carcinoma. *Cancer*. 2000; 88(6):1294–303. [PubMed: 10717609]
 27. Average Wage Index (AWI). [cited June 29, 2010]; Available from: <http://socialsecurity.gov/oact/COLA/AWI.html>
 28. Kinsella, K.; He, W. An Aging World: 2008. [cited May 6, 2010]; Available from: www.census.gov/prod/2009pubs/p95-09-1.pdf
 29. O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou J-I, Heise CP, et al. Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features. *Journal of Clinical Oncology*. Jul 25.2011 2011.
 30. O'Connell JB, Maggard MA, Ko CY. Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging. *J Natl Cancer Inst*. Oct 6; 2004 96(19):1420–5. 2004. [PubMed: 15467030]
 31. Kerr D, Gray R, Quirke P, Watson D, Yothers G, Lavery I, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. *J Clin Oncol*. 2009; 27(15 suppl):169s.
 32. Pogue-Geile K. Use of a prognostic (prog) gene index and nodal status to identify a subset of stage II and III colon cancer patients (pts) who may not need oxaliplatin (ox)-containing adjuvant chemotherapy. *J Clin Oncol*. 2010; 28(15 Suppl):a3516.

33. Rosenberg R, Maak M, Simon I. Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. *J Clin Oncol.* 2011; 29:358.
34. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, et al. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. *New England Journal of Medicine.* Jun 30; 2005 352(26): 2696–704. doi: 10.1056/NEJMoa043116. 2005. [PubMed: 15987918]
35. Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustova I, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. *Br J Cancer.* 2006; 94(8):1122–9. [PubMed: 16622438]
36. de Gramont A, Tournigand C, Andr T, Larsen AK, Louvet C. Adjuvant Therapy for Stage II and III Colorectal Cancer. *Seminars in Oncology.* 2007; 34(Supplement 1):S37–S40. [PubMed: 17449351]
37. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07. *J Clin Oncol.* Jun 1; 2007 25(16): 2198–204. 2007. [PubMed: 17470851]
38. Viele CS. Overview of chemotherapy-induced diarrhea. *Seminars in Oncology Nursing.* 2003; 19(4 suppl 3):2–5. [PubMed: 14702926]
39. Best, J.; Garrison, L.; Hollingworth, W.; Ramsey, S.; Veenstra, D. Quality of Life Research. 2010. Preference values associated with stage III colon cancer and adjuvant chemotherapy.
40. Camilleri-Brennan J, Steele RJC. The impact of recurrent rectal cancer on quality of life. *European Journal of Surgical Oncology.* 2001; 27(4):349–53. [PubMed: 11417978]
41. Fryback DG, Dasbach EJ, Klein R, Klein BEK, Dorn N, Peterson K, et al. The Beaver Dam health outcomes study. *Medical Decision Making.* 1993; 13(2):89–102. [PubMed: 8483408]

Figure 1.
Adjuvant Chemotherapy and Follow-up Period Models

A - ICER of FOLFOX as compared to 5FU/LV **B - ICER of 5FU/LV as compared to Observation**

Figure 2.
Tornado Diagram Summarizing the Results of One-way Sensitivity Analysis

Figure 3.
Sensitivity Analysis Over Age

Figure 4.
Probabilistic Sensitivity Analysis

Table 1

Parameters used for calibration

Parameters	Value		Data source
<i>Overall toxicity after adjuvant chemotherapy</i>	FOLFOX	5FU/LV	
Percentage of major toxicity P_{ma}	50.9%	6.6%	Andre et al., 2004[4]
Percentage of minor toxicity P_{mi}	41.1%	60.3%	
Percentage of well P_w	8%	33.1%	
Percentage of death due to adjuvant chemotherapy P_d	0.5%	0.5%	de Gramont et al., 2007[36]
Percentage of quitting adjuvant chemotherapy P_q	25.3%	13.5%	Andre et al., 2009[12]

Table 2

Probability parameters

<i>Toxicity after adjuvant chemotherapy period</i>	Value			Data source
6 months after chemotherapy				Andre et al., 2004[4]
Percentage of minor toxicity	39.7%			
Percentage of major toxicity	1.3%			
18 months after chemotherapy				
Percentage of minor toxicity	23.2%			
Percentage of major toxicity	0.5%			
<i>Follow-up period</i>	FOLFOX	5FU/LV	Observation	
<i>Relapse and Survival Data</i>				
5-year relapse probability	*16.3% (±20%)	*20% (±20%)	†24%(±20%)	
1- year relapse probability	*2%	*4%	†5.5%	†QUASAR Collaborative Group, 2007[7], *Andre et al., 2009[10], ‡IMPACT B2 Investigators, 1999[6] ‡O'Connell, 2004 [30]
2- year relapse probability	*9%	*11%	†13%	
3- year relapse probability	*11.5%	*14%	†19%	
4- year relapse probability	*14%	*18%	†21%	
5- year relapse probability	*16.3%	*20%	†24%	
5-year survival probability	*87% (82–90)	*87% (82–90)	†80(75–82)%	
<i>Transition Probability</i>				
State 1 (free of cancer) to state 2 (alive with relapse)				
State 1 to state 2 in year 1	0.02	0.04	0.055	Calculated from annual relapse probability from year 1 to year 5
State 1 to state 2 in year 2	0.0714	0.0729	0.0794	
State 1 to state 2 in year 3	0.0275	0.0337	0.0690	
State 1 to state 2 in year 4	0.0282	0.0465	0.0247	
State 1 to state 2 in year 5	0.0267	0.0244	0.0380	
State 1 to state 2 > year 5	0	0	0	Assumed
State 2 (alive with relapse) to state 3 (death)	0.2978 (0.2– 0.5075)	0.2252 (0.1554–0.3676)	0.2935 (0.2423–0.4217)	Calculated from annual relapse probability from year 1 to year 5 and 5-year survival probability
State 1(free of cancer) to state 3 (death)				
State 1 to state 3 in year 1	0.009493			Arias, 2007[19]
State 1 to state 3 in year 2	0.010449			
State 1 to state 3 in year 3	0.011447			
State 1 to state 3 in year 4	0.012428			
State 1 to state 3 in year 5	0.013408			
Expectation of life at age 65 (year)	18.7			
Discount rate	3% (0–5%)			

Table 3

Calculation of Transition Probabilities from State 2 to 3

	FOLFOX	5FU/LV	Observation
Death in year 1	$0.02x$	$0.04y$	$0.055z$
Death in year 2	$(0.09-0.02x)x$	$(0.11-0.04y)y$	$(0.13-0.055z)z$
Death in year 3	$(0.115-0.09x+0.02x^2)x$	$(0.14-0.11x+0.04y^2)y$	$(0.19-0.13z+0.055z^2)z$
Death in year 4	$(0.14-0.115x+0.09x^2-0.02x^3)x$	$(0.18-0.14y+0.11y^2-0.04y^3)y$	$(0.21-0.19z+0.13z^2-0.055z^3)z$
Death in year 5	$(0.163-0.14x+0.115x^2-0.09x^3+0.02x^4)x$	$(0.2-0.18y+0.14y^2-0.11y^3+0.04y^4)y$	$(0.24-0.21z+0.19z^2-0.13z^3+0.055z^4)z$
5-year death probability	0.13	0.13	0.20
Transition probability from state 2 to 3★	$x=0.2978$	$y=0.2252$	$z=0.2935$

★Transition probability from relapse to death of all causes (disease-related and overall mortality)

Table 4

Costs and ratio parameters

	FOLFOX	5FU/LV	Observation	Data source
<i>Adjuvant chemotherapy period</i>	\$29,000(±20%)	\$6,500(±20%)	0	Aballéa et al., 2007 [23]
<i>Adjuvant chemotherapy induced toxicity cost and ratio</i>				
Grade 3–4 Neutropenia	\$132 (\$118–\$156)	\$132 (\$118–\$156)	0	Tumeh et al., 2009 [3]
Percentage of Grade 3–4 neutropenia	41.1%	4.7%	0	Andre et al., 2004 [4]
Febrile neutropenia (Hospitalization)	\$3522 (\$1879–\$8291)	\$3522 (\$1879–\$8291)	0	Tumeh et al., 2009 [3]
Percentage of Febrile Neutropenia	*1.8% † (0–2.4%)	*0.2% † (0–0.9%)	0	*Andre et al., 2004 [4] †Kuebler et al., 2007 [37]
Grade 3–4 diarrhea	\$117 (\$97–\$137)	\$117 (\$97–\$137)	0	Tumeh et al., 2009 [3]
Percentage of Grade 3–4 diarrhea	*10.8% † (0–30%)	*6.6% † (0–15%)	0	*Andre et al., 2004 [4] †Viele et al., 2003 [38]
<i>Relapse cost</i>	\$58,800 (±20%)	\$61,200 (±20%)	\$61,200 (±20%)	Aballéa et al., 2007 [23]

Table 5

Utility parameters

<i>Adjuvant chemotherapy period</i>		
Well	0.84	Ramsey et al, 2000 [26]
Minor toxicity	0.73(0.6–0.84)	Best et al., 2010 [39]
Major toxicity	0.59(0.49–0.68)	
Alive with relapse	0.47($\pm$ 20%)	Camilleri-Brennan et al., 2001 [40]
<i>Follow-up period</i>		
6–12 th month for chemotherapy group	0.84	Ramsey et al., 2000 [26]
1 st year for observation group	0.84	
2 nd year	0.85	
3 rd year	0.87	
4 th year	0.79	
5 th year	0.79	
65–74 years old	0.84	Fryback et al., 1993 [41]
$\geq$ 75 years old	0.82	Fryback et al., 1997 [25]
$\geq$ 65 years old	0.83	(0.84+0.82)/2

Table 6

Cost-effectiveness Analysis of the Base Case (Discounting at 3%)

Base Case		QALYs	ICER
Chemotherapy Group (FOLFOX)	\$35,271	11.65	\$54,359/QALY
Chemotherapy Group (5FU/LV)	\$15,158	11.28	\$14,584/QALY
Observation Group	\$9,616	10.9	
Without adjustment for quality of life		Lys	ICER
Chemotherapy Group (FOLFOX)	\$35,271	14.28	\$52,929/LY
Chemotherapy Group (5FU/LV)	\$15,158	13.90	\$9,896/LY
Observation Group	\$9,616	13.34	